Inflammation Research Association: 12th international conference

Abstract

The Inflammation Research Association held its 12th international meeting at the Sagamore at Bolton Landing in New York State (3 – 7 O-ctober 2004). These meetings were originally intended for scientists from the pharmaceutical industry to get together and discuss the latest developments in inflammation drug discovery, and it remains an industry-dominated affair. The conference covered some highly topical issues such as cyclooxygenase-2 inhibitors (rofecoxib/Vioxx® [Merck & Co., Inc.] was withdrawn from the market only a few days before the conference), along with areas of ongoing interest to the pharmaceutical and biotechnology industry, including p38 MAPK inhibitors, nuclear hormone receptor modulators and prostaglandin receptor antagonists. This review will cover the main themes that emerged during the meeting.

• inflammation
• kinase
• metalloprotease
• nuclear hormone receptor
• prostaglandin
• tumour necrosis factor